Wandercraft, a maker of self-balancing robotic mobility systems, has secured $75 million in funding to accelerate AI-powered robotics.
This influx of capital arrives during a time of rapid growth, increased global visibility, and product innovation in clinical, consumer, and industrial robotics.
The Series D round came with major contributions from Renault Group, Bpifrance, the European Investment Bank, Teampact Ventures and Quadrant Management.
The new funding will help propel Wandercraft into its next phase of growth: bringing Eve, the world’s first self-balancing personal exoskeleton, to market as early as 2026; expanding clinical adoption of its flagship rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot.
“The momentum we’ve achieved over the past few years is extraordinary,” said Matthieu Masselin, CEO of Wandercraft, in a statement. “We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
The news comes off the back of Wandercraft’s announcement with Renault Group, whereby the car manufacturer now has a minority stake ownership and a strategic partnership with Wandercraft. The partnership brings Renault Group’s industrial expertise to scale up production of Wandercraft’s exoskeletons and industrial robots. Renault is Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days.
Calvin-40 is an industrial-grade robot intended for physically demanding tasks – set for production deployment within 40 weeks at Renault factories. The first humanoid robot developed by a European company, Calvin-40’s speedy development was made possible by using Wandercraft’s existing leading-edge robotics platform, rapid development process, and a collaboration with NVIDIA, leveraging their VLA (Visual Language Model) and Jetson AI computing platform. The partnership with Renault lays the groundwork for cost-efficient scaling of Eve and the broader Calvin humanoid family.
Looking ahead, the Series D funding will accelerate:
Commercial deployment of Eve, the personal exoskeleton, in home and outdoor environments.
A new phase of growth and support for Atalante X.
Industrial development and rollout of Calvin-40 and the broader Calvin humanoid family.
Today’s news follows a period of major growth since the company raised its Series C round of $45 million, led by Quadrant Management, which fueled U.S. commercial expansion and helped drive a tenfold increase in revenues. Other participants in the Series D round include LBO France, Mutuelles Impact – Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
Wandercraft’s momentum comes from its dedication to restoring independence through self-balancing, hands-free robotic systems that allow upright movement without crutches or walkers.
The technology is powered by AI and has been life-tested, refined through billions of simulations and tens of millions of real-world steps.
The result is a growing list of industry firsts and clinical achievements: Clinical innovation, powered by AI; received its first FDA clearance for rehabilitation exoskeleton Atalante X for stroke; followed by a second FDA clearance in less than a year, then expanding its use in U.S. hospitals and clinics; launched the world’s first clinical trial of a self-balancing personal exoskeleton, Eve, designed to help individuals with severe mobility impairments walk hands-free at home and in their communities; deployed Atalante X in more than 100 hospitals and rehabilitation centers globally, including the Kessler Foundation, the Villa Beretta Rehabilitation Research Innovation Institute, and Vivantes Klinikum Spandau and Schön Klinik.
Wandercraft was evaluated in more than 20 clinical studies; key findings include meaningful improvements in walking speed, balance, independence, and postural control – often accompanied by perception of reduced pain, spasticity, and increased muscle strength. And it enabled 2,500 people with mobility disabilities to take more than 14 million steps to date, rediscovering the freedom of upright movement once considered out of reach.
The company also widened rehabilitation access in New York. The company opened “Walk in New York by Wandercraft,” the first walk center to offer regular exoskeleton walking sessions for people with mobility disabilities with conditions such as stroke, MS, Parkinson’s disease, and SCI.
The facility sits within Cure, a healthcare innovation campus in New York City, which also houses Wandercraft’s U.S. headquarters. The company intends to establish the center as the first regional hub for Eve’s deployment ahead of its anticipated U.S. launch in 2026.
Product Innovation and Recognition
Wandercraft showcased personal exoskeleton Eve at the 2024 Olympic and Paralympic Torch Relay, symbolizing a new global standard in mobility technology. It was also featured by Nvidia at CES 2025 and their annual technology conference Nvidia GTC conference in March. Nvidia recognized Wandercraft’s use of Nvidia’s state-of-the-art technology and physical AI to enable autonomous, hands-free walking.
Wandercraft invites individuals to learn more about its ongoing clinical trial for Eve, the personal exoskeleton. The study evaluates real-world usability, focusing on ease of movement, endurance, and integration into daily life. Adults aged 18 and older with complete or incomplete motor SCI (at or above T6) may be eligible to participate, provided they have – or can secure – a physically able companion for support. To inquire or apply, email clinicaltrials@wandercraft.health. The company is hiring.
Wandercraft is a robotics company on a mission to restore mobility and expand what’s possible through self-balancing, AI-powered systems. Founded in 2012, Wandercraft is globally recognized for creating the world’s first self-balancing walking exoskeleton, Atalante X, which is used in more than 100 rehabilitation centers across four continents to assist individuals with disabilities in taking more than a million steps each month. It has more than 30 patents.